LLY vs PODD: fair value comparison
Eli Lilly and Company and Insulet Corporation · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, PODD currently sits closer to the top of our discount ranking. PODD carries the stronger quality grade.
| LLY | PODD | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $1,149.36 | $147.48 |
| 12-month range | $862.86–$1,160.00 | $148.13–$318.77 |
| Sector rank | #11 of 113 Healthcare | #4 of 113 Healthcare |
| Quality grade | D | A |
| Leverage | High | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: LLY fair value analysis · PODD fair value analysis